Akbar S M, Yamamoto K, Abe M, Ninomiya T, Tanimoto K, Masumoto T, Michitaka K, Horiike N, Onji M
Third Department of Internal Medicine, Ehime University School of Medicine, Ehime, Japan.
Eur J Clin Invest. 1999 Sep;29(9):786-92. doi: 10.1046/j.1365-2362.1999.00533.x.
Traditional herbal medicine, sho-saiko-to (TJ-9), improves subjective symptoms, and a recently developed vaccine therapy reduces the viral replication in some chronic hepatitis B virus (HBV)-carriers. The study presented here considers the impact of a combination of vaccine therapy and TJ-9 and the mechanism underlying the therapeutic effect of TJ-9.
HBV-transgenic mice (HBV-Tg) expressing similar levels of HBV-related antigens and HBV DNA were used as an animal model of HBV-carrier state, and were assigned to receive either a TJ-9-enriched diet or a monthly injection of vaccine containing hepatitis B surface antigen (HBsAg), or both, for 12 consecutive months.
Twelve months after starting the therapy, 9% (1 of 11), 61% (11 of 18), and 100% (10 of 10) of HBV-Tg receiving only the TJ-9-treatment, only the monthly vaccine, and both the TJ-9 and vaccine, respectively, responded to therapy and became completely negative for HBsAg. Spleen lymphocytes and antigen presenting cells (APC) from TJ-9-treated HBV-Tg produced significantly higher levels of IgM, IgG and antibodies to keyhole limpet hemocyanin (KLH) and showed significantly higher stimulatory capacity in allogenic mixed leukocyte reaction (MLR) compared with the spleen cells and APC from HBV-Tg receiving normal diet without TJ-9 (P < 0.05).
These data confirm the therapeutic role of TJ-9 during HBV infection and inspire optimism of a widespread use of TJ-9 during immune therapies.
传统草药小柴胡汤(TJ - 9)可改善主观症状,且最近研发的疫苗疗法可减少部分慢性乙型肝炎病毒(HBV)携带者体内的病毒复制。本文所呈现的研究探讨了疫苗疗法与TJ - 9联合使用的影响以及TJ - 9治疗效果的潜在机制。
将表达相似水平HBV相关抗原和HBV DNA的HBV转基因小鼠(HBV - Tg)用作HBV携带者状态的动物模型,并将其分为三组,分别连续12个月接受富含TJ - 9的饮食、每月注射含乙型肝炎表面抗原(HBsAg)的疫苗或两者同时使用。
治疗开始12个月后,仅接受TJ - 9治疗、仅接受每月疫苗注射以及同时接受TJ - 9和疫苗注射的HBV - Tg小鼠中,分别有9%(11只中的1只)、61%(18只中的11只)和100%(10只中的10只)对治疗有反应,且HBsAg完全转阴。与未接受含TJ - 9正常饮食的HBV - Tg小鼠的脾细胞和抗原呈递细胞(APC)相比,接受TJ - 9治疗的HBV - Tg小鼠的脾淋巴细胞和APC产生的IgM、IgG以及抗钥孔血蓝蛋白(KLH)抗体水平显著更高,并且在同种异体混合淋巴细胞反应(MLR)中显示出显著更高的刺激能力(P < 0.05)。
这些数据证实了TJ - 9在HBV感染过程中的治疗作用,并为其在免疫治疗中广泛应用带来了乐观前景。